Walleye Capital
COGT icon

Walleye Capital’s Cogent Biosciences COGT Stock Holding History

Walleye Capital’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-114,463
Closed -$4.07M – 4477
2025
Q4 		$4.07M Buy
+114,463
New +$3.22M 0.01% 1301
2025
Q2 		– Sell
-533,884
Closed -$3.2M – 4572
2025
Q1 		$3.2M Sell
533,884
-402,907
-43% -$3.16M 0.01% 1088
2024
Q4 		$7.31M Buy
936,791
+379,465
+68% +$3.78M 0.02% 835
2024
Q3 		$6.02M Buy
+557,326
New +$5.43M 0.01% 1036
2023
Q4 		– Sell
-552,908
Closed -$5.39M – 5007
2023
Q3 		$5.39M Sell
552,908
-44,318
-7% -$526K 0.01% 982
2023
Q2 		$7.07M Sell
597,226
-189,370
-24% -$2.17M 0.03% 556
2023
Q1 		$8.49M Buy
786,596
+342,493
+77% +$4.38M 0.13% 179
2022
Q4 		$5.13M Buy
444,103
+309,955
+231% +$3.84M 0.09% 258
2022
Q3 		$2M Buy
134,148
+123,559
+1,167% +$1.69M 0.04% 556
2022
Q2 		$96K Buy
+10,589
New +$72.3K ﹤0.01% 1759

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Walleye Capital's COGT Position: Q1 2026 in Review

Walleye Capital sold out of Cogent Biosciences (COGT) in Q1 2026, closing a stake of 114,463 shares — an estimated $4.07M sold.

Walleye Capital first reported a position in COGT in Q2 2022 and held it in 10 quarters. The position peaked at $8.49M in Q1 2023. 305 funds tracked by Wall St. Rank hold COGT as of Q1 2026.

  • Walleye Capital reported no remaining Cogent Biosciences position as of Q1 2026 after selling out during the quarter.
  • Walleye Capital sold 114,463 Cogent Biosciences shares in Q1 2026, an estimated $4.07M.
  • Walleye Capital first reported a position in Cogent Biosciences in Q2 2022 and held it in 10 quarters.
  • Walleye Capital's Cogent Biosciences position peaked at $8.49M in Q1 2023.
  • 305 funds tracked by Wall St. Rank held Cogent Biosciences as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.